Melanotan MT-2 10mg

Melanotan II (MT-2) 10mg is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH) designed for research and laboratory use. MT-2 is a non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R) that has been investigated in preclinical and clinical research settings for its effects on melanogenesis, sexual function, appetite regulation, and energy homeostasis. It served as the parent compound from which the more selective PT-141 (bremelanotide) was derived. Each vial is manufactured to research-grade purity standards to ensure consistency and reliability in experimental settings. Ideal for qualified researchers and institutions studying melanocortin receptor pharmacology, pigmentation biology, and neuroendocrine signalling. Store at 2–8°C. For research purposes only. Not intended for human or veterinary use.

Specifications: Active Ingredient: Melanotan II (MT-2) Chemical Name: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ Molecular Formula: C₅₀H₆₉N₁₅O₉ Molecular Weight: 1,024.18 g/mol CAS Number: 121062-08-6 Structure: Cyclic heptapeptide α-MSH analogue Receptor Activity: Non-selective MC1R, MC3R, MC4R, MC5R agonist Purity: ≥95% (HPLC) Form: Lyophilised powder Appearance: White to off-white lyophilised powder Storage: 2–8°C (refrigerated) Shelf Life: 2 years from manufacture date Reconstitution: Sterile water or bacteriostatic saline Intended Use: Laboratory and research applications only

Storage Before Reconstitution: Store in original sealed vial at 2–8°C, protected from direct sunlight and moisture. Stable for up to 2 years when stored properly. Storage After Reconstitution: Store reconstituted solution at 2–8°C and use within 3–7 days. Discard after 24 hours at room temperature. Maintain sterile technique to prevent contamination. Avoid repeated freeze-thaw cycles. For research use only. Not intended for human or veterinary use.

Research References

The following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.

1. Melanotan II: Design and Melanocortin Receptor Pharmacology
   Hadley ME, et al. (1996). Discovery and development of novel melanogenic drugs. Melanotan-I and -II. Pharmaceutical Biotechnology, 9, 575–595. https://doi.org/10.1007/978-1-4615-5833-0_29
   Foundational paper describing the design and synthesis of Melanotan I and II as cyclic α-MSH analogues, characterising their melanocortin receptor binding profiles and establishing the pharmacological basis for MT-2 as a potent, non-selective MC receptor agonist.
2. MT-2 and Melanogenesis: MC1R-Mediated Pigmentation
   Dorr RT, et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 58(20), 1777–1784. https://doi.org/10.1016/0024-3205(96)00160-9
   Phase I clinical research study evaluating MT-2’s pharmacokinetics and melanogenic activity, demonstrating dose-dependent skin pigmentation via MC1R activation and providing the key translational pharmacodynamic reference for MT-2 melanogenesis research.
3. MT-2 and MC4R-Mediated Sexual Function
   Wessells H, et al. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology, 160(2), 389–393. https://doi.org/10.1016/S0022-5347(01)62899-X
   Double-blind, placebo-controlled crossover study demonstrating MT-2’s pro-erectile activity via central MC4R activation, establishing the mechanistic basis for melanocortin agonism in sexual function research and providing the pharmacological rationale for the subsequent development of PT-141.
4. MT-2 and MC4R in Appetite and Energy Homeostasis
   Fan W, et al. (1997). Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature, 385(6612), 165–168. https://doi.org/10.1038/385165a0
   Landmark study establishing MC4R as the primary hypothalamic receptor mediating melanocortin-induced anorexia and energy expenditure, providing the mechanistic context for MT-2’s appetite-suppressing effects observed in preclinical research models.
5. Melanocortin Receptor Subtypes: Pharmacology and Distribution
   Wikberg JE, et al. (2000). New aspects on the melanocortins and their receptors. Pharmacological Research, 42(5), 393–420. https://doi.org/10.1006/phrs.2000.0725
   Comprehensive review of MC1R–MC5R receptor subtypes, tissue distribution, and signalling pathways, providing the complete receptor pharmacology framework for understanding MT-2’s broad non-selective agonist activity across multiple melanocortin receptor subtypes.

All references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.